Investigational drug · Phase 3
CRB-701
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumor, Adult, Oropharyngeal Carcinoma (OPC).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "CRB-701"
First trial start
2024
Apr 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CRB-701", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor, Adult
- Oropharyngeal Carcinoma (OPC)
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "CRB-701" as an intervention, largest first.
- A Phase 1/2 Study to Investigate CRB-701 in Solid TumorsPivotal-lookingRecruiting
Corbus Pharmaceuticals Inc.Industry
NCT06265727 · 348 participants (planned) · Start Apr 1, 2024 · Primary completion Jan 16, 2027
Drug: CRB-701; Anti-PD-1 · For: Solid Tumor, Adult
Sites: Birmingham, Alabama; Duarte, California; San Diego, California · 41 sites in all
- A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell CarcinomaPivotal-lookingRecruiting
Corbus Pharmaceuticals Inc.Industry
NCT07768189 · 260 participants (planned) · Start Sep 29, 2026 · Primary completion Dec 2027
Drug: CRB-701; capcitabine and 2 more · For: Oropharyngeal Carcinoma (OPC)
Sites: Huntsville, Alabama; Tucson, Arizona; Duarte, California · 111 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- CRB-701: A Second-generation Nectin-4-Targeted Antibody-Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors.
Sun Z, Dan M, Lv L, et al. · Cancer Res Commun 2026
Also in development for Solid Tumor, Adult
- VisugromabCTL-002, Visugromab RDEPhase 36 trials
CatalYm GmbH · Adult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Unresectable or Metastatic Hepatocellular Carcinoma
- anzutresgene autoleucelIMA203 Product, IMA203 product- flat dosePhase 32 trials
Immatics US, Inc. · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- HMPL-453Phase 32 trials
Hutchmed · Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult, Solid Tumor
- VT3989Phase 32 trials
Vivace Therapeutics, Inc · Pleural Mesothelioma, Mesothelioma, Solid Tumor, Adult
- DabogratinibTYRA-300Phase 24 trials
Tyra Biosciences, Inc · FGFR3 Gene Mutation, FGFR3 Gene Alteration, Achondroplasia
- VS-7375Phase 24 trials
Verastem, Inc. · G12D Mutated KRAS, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
- Tmod CAR T-cell TherapyA2B530, A2B694Phase 23 trials
A2 Biotherapeutics Inc. · Solid Tumor, Adult, Colorectal Cancer, Colorectal Adenocarcinoma
- AK119Phase 22 trials
Akeso · Colorectal Cancer, Solid Tumor, Adult
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.